Procyon Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.97M | Sell |
4,428
-14,170
| -76% | -$6.31M | 0.18% | 106 |
|
|
2025
Q1 | $9.02M | Buy |
18,598
+3,963
| +27% | +$1.92M | 0.55% | 42 |
|
|
2024
Q4 | $5.89M | Sell |
14,635
-375
| -2% | -$151K | 0.37% | 57 |
|
|
2024
Q3 | $6.98M | Buy |
15,010
+157
| +1% | +$73K | 0.48% | 47 |
|
|
2024
Q2 | $6.96M | Buy |
14,853
+530
| +4% | +$248K | 0.52% | 48 |
|
|
2024
Q1 | $5.99M | Buy |
14,323
+636
| +5% | +$266K | 0.46% | 52 |
|
|
2023
Q4 | $5.57M | Buy |
13,687
+939
| +7% | +$382K | 0.47% | 45 |
|
|
2023
Q3 | $4.43M | Buy |
12,748
+5,375
| +73% | +$1.87M | 0.45% | 51 |
|
|
2023
Q2 | $2.59M | Buy |
7,373
+4,028
| +120% | +$1.42M | 0.33% | 72 |
|
|
2023
Q1 | $1.05M | Buy |
3,345
+643
| +24% | +$203K | 0.18% | 127 |
|
|
2022
Q4 | $780K | Buy |
2,702
+1,424
| +111% | +$411K | 0.14% | 148 |
|
|
2022
Q3 | $370K | Sell |
1,278
-88
| -6% | -$25.5K | 0.09% | 205 |
|
|
2022
Q2 | $385K | Buy |
1,366
+37
| +3% | +$10.4K | 0.08% | 217 |
|
|
2022
Q1 | $347K | Buy |
+1,329
| New | +$347K | 0.07% | 230 |
|
|
2020
Q3 | – | Sell |
-272
| Closed | -$79K | – | 1025 |
|
|
2020
Q2 | $79K | Hold |
272
| – | – | 0.04% | 319 |
|
|
2020
Q1 | $65K | Hold |
272
| – | – | 0.04% | 301 |
|
|
2019
Q4 | $60K | Buy |
+272
| New | +$60K | 0.04% | 327 |
|